Navigation Links
Roche NimbleGen and BGI Develop Advanced MHC Region Capture Technology for Human Disease and Biomedical Research
Date:11/28/2011

founded in Beijing, China, in 1999 with the mission to become a premier scientific partner for the global research community. The goal of BGI is to make leading-edge genomic science highly accessible, which it achieves through its investment in infrastructure, leveraging the best available technology, economies of scale, and expert bioinformatics resources. BGI, and its affiliates, BGI Americas and BGI Europe, have established partnerships and collaborations with leading academic and government research institutions as well as global biotechnology and pharmaceutical companies, supporting a variety of disease, agricultural, environmental, and related applications.

BGI has a proven track record of excellence, delivering results with high efficiency and accuracy for innovative, high-profile research: research that has generated over 170 publications in top-tier journals such as Nature and Science. BGI's many accomplishments include: sequencing one percent of the human genome for the International Human Genome Project, contributing 10 percent to the International Human HapMap Project, carrying out research to combat SARS and German deadly E. coli, playing a key role in the Sino-British Chicken Genome Project, and completing the sequence of the rice genome, the silkworm genome, the first Asian diploid genome, the potato genome, and, more recently, have sequenced the human Gut Metagenome, and a significant proportion of the genomes for the1000 Genomes Project,

For more information about BGI, please visit http://www.genomics.cn

For life science research only. Not for use in diagnostic procedures.

NIMBLEGEN and SEQCAP are trademarks of Roche.

All other product names and trademarks are the property of their respective owners.

For further information please contact:

Roche Diagnostics
Dr. Burkhard Ziebolz
Phone: +49 8856 604830
Email:

SOURCE Roche Diagnostics GmbH
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
2. Arius announces leading independent proxy firm, RiskMetrics ISS Canada, recommends shareholders vote for the arrangement involving its acquisition by Roche
3. Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration
4. Roche completes acquisition of ARIUS
5. Exiqon A/S Today Announces a Grant of License to Roche Diagnostics
6. InformationWeek Puts Roche Diagnostics on Top 500 Innovative Tech Users List
7. Axial Biotech Appoints Retired Roche Diagnostics Executive to Board
8. Roche Purchases Shares in Tender Offer For Memory Pharmaceuticals Corp.
9. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
10. Roche Intends to Commence Tender Offer to Acquire All Shares of Genentech for US$ 86.50 Per Share in Cash
11. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... , June 2, 2015   Y-Prime, ... attending the BIO Exhibition 2015 in ... the world,s largest biotechnology gathering, allows influential decision ... executives, where they can evaluate emerging technologies such ... eClinical expertise in the design, implementation and management ...
(Date:6/2/2015)... June 2, 2015   BioClinica ® , Inc., ... today announced that David Peters , an accomplished ... Vice President and Chief Financial Officer (CFO) and will ... Peters brings more than 25 years of financial and ... has extensive and deep knowledge in all areas of ...
(Date:6/2/2015)... , June 2, 2015   Sigma-Aldrich Corporation ... and Technology company, announced today it has entered ... to launch genetically engineered human neural differentiated cells ... research of neurological diseases. These new products, in ... and versatile tools for the study of central ...
(Date:6/2/2015)... June 2, 2015 /PRNewswire/ -- China Cord Blood Corporation (NYSE: ... China,s leading provider of cord blood collection, ... services, today announced that the Special Committee of the Company,s ... Lokey ( China ) Limited as its ... LLP as its United States legal ...
Breaking Biology Technology:YPrime at BIO Exhibition in Philadelphia and DIA in Washington DC during the month of June 2BioClinica Names David Peters New Chief Financial Officer 2Sigma-Aldrich to Launch XCell Science Genetically Engineered iPSC-Derived Neural Disease Cells 2Sigma-Aldrich to Launch XCell Science Genetically Engineered iPSC-Derived Neural Disease Cells 3China Cord Blood Corporation's Special Committee Appoints Independent Financial Advisor and Legal Counsel to Evaluate Non-binding "Going Private" Proposal 2China Cord Blood Corporation's Special Committee Appoints Independent Financial Advisor and Legal Counsel to Evaluate Non-binding "Going Private" Proposal 3
... ... ... 2010 -- ProRepro today announced it has become an Autodesk authorized value-added reseller (VAR). ... Southern California. ProRepro’s qualified staff demonstrates in-depth technical and industry knowledge and a commitment ...
... INDIANAPOLIS and WALTHAM, Mass. , May 6, 2010 ... Company (NYSE: LLY ) and Alkermes, Inc. (Nasdaq: ALKS ... classified the BYDUREON™ (exenatide for extended-release injectable suspension) complete response as a ... (PDUFA) action date of October 22, 2010 . , ...
... May 6 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. ( ... company specialized in oncology and endocrinology, today announced that ... Administration (FDA), orphan-drug designation for AEZS-108, its doxorubicin targeted ... is currently in a Phase 2 trial in advanced ...
Cached Biology Technology:ProRepro Becomes a Value-Added Reseller for Autodesk 2BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 2BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 3BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 4BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 5BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 6BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 7BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010 8Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer 2Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer 3
(Date:5/21/2015)... The Sync Project™ , a global collaboration harnessing ... a collaborative partnership with Berklee,s Institute for Creative ... on original research, joint course development and an internship ... Sync Project and BerkleeICE are exploring the launch of ... academic year.  The course will focus ...
(Date:5/19/2015)... Fingerprint Cards (FPC) has received an ... and FPC1035 from one if its module partners. Deliveries are ... 2015 and the sensors will be used by smartphone manufacturers ... 2015 hereby amount to 740 MSEK to date. In addition ... and a number of smaller orders not separately communicated amounting ...
(Date:5/18/2015)... May 18, 2015 Fingerprint Cards (FPC) ... FPC1025, FPC1145, FPC1155 and FPC1035 from one if its module ... and including Q3 2015 and the sensors will be used ... order values for 2015 hereby amount to 740 MSEK to ... of 140 MSEK and a number of smaller orders not ...
Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... University of Texas at San Antonio will bring together ... countries when it hosts the inaugural UTSA North American ... Building at the UTSA Downtown Campus. The summit will ... Canada and Mexico addressing the energy needs for future ...
... A novel cell therapy using retinal pigment epithelial ... implanted in the brain can improve the symptoms ... (PD). Rush University Medical Center neurosurgeon Dr. ... University, Atlanta found the therapy Spheramine was well-tolerated ...
... safer along Massachusetts Bay,s busy shipping lanes this spring, ... buoys recognize whales, distinctive calls and route the information ... system, giving ships the chance to avoid deadly collisions. ... >) -- developed at the Cornell Lab of Ornithology ...
Cached Biology News:UTSA hosts North American Energy Summit May 1-2 2Cell-based therapy shows promise in patients with Parkinson's disease 2Cell-based therapy shows promise in patients with Parkinson's disease 3Warning buoys for right whales installed along Massachusetts Bay 2
... Immobilized] Goat Immunogen: Goats ... (MASMTGGQQMG). Antibody was isolated by affinity ... support. Goat anti- human T7 affinity purified ... cyanogens bromide method. Specificity: ...
C/EBPdelta Antibody Shipping Temperature: Cold Storage Temperature: -20C...
Mouse monoclonal [11C9] to Zeralenone ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to BSA: Zeralenone...
Anti-human C5a/C5a des-Arg (neo-epitode), Clone 2952, Monoclonal Antibody...
Biology Products: